Clicks Group Limited ($CLS)

Good afternoon. Thank you for joining the webcast of our interim results for the 6 months ended 28th February 2026. I'm Bertina Engelbrecht, Chief Executive Officer of the Clicks Group. I am joined by Gordon Trail, our Chief Financial Officer, who is in a completely different time zone. Gordon and I will take you the presentation of our interim results, and we'll respond to any questions you may have after the conclusion of our presentation. This slide sits on the outline of our presentation. I will, as usual, kick off with a review of our performance over the past 6 months. Gordon will then present an overview of the financial results. I'll walk you through the trading performances of our operating business units, starting with clicks followed by [indiscernible], and I will then close with the outlook for the group. Please feel free to submit any questions you may have via the webcast platform during or after the conclusion of our presentation. [indiscernible] your questions to which Gordon and I will respond. I will now take you through the review of the period. It has been a tough 6 months. Despite some interest rate relief and signs of a slow recovery in the economic environment, Trading conditions remain constrained, especially for middle income households. Competition intensified as new players enter the market. Traditional players extended into health and beauty categories giving rise to heightened levels of promotions aimed at capturing a greater share of the consumer wallet. Over the period, we experienced lost sales exacerbated by low availability due to the rollout of our warehouse management system in the recent DC over the peak training period. We invested in the expansion of our store and pharmacy network, technology enablement, and progress both our people and sustainability agenda. The number of pharmacy drop-ins were, however, lower than planned. In the period under review, we opened our 1,000th store at our 797 pharmacy [indiscernible] in the Eastern [indiscernible]. We've also increased our primary care clinics to 226 as we deepen partnerships with medical funders. Our cloud customer mention increased by 800,000 new members over the period to 12.9 million active mines and contributed 83.7% of retail plan over -- we continue to be recognized as one of the strongest brands. [Audio Gap] If we consider the group financial highlights highlights. Group turnover increased by 7% from the Retail turnover grew 5.4% and UPD's reported [indiscernible] increased by 13% with a strong performance from wholesale and our preferred bulk contracts. The group trading margin at 9.1% was maintained despite increased promotional activity and faster growth of GLP-1s. The diluted headline earnings per share for the group increased to ZAR 6.53 per share, up 8.1% on the prior period. In the 6 months, $1.9 billion was generated in cash from operations after working capital. The group's return on equity at 45.7% has remained strong. To note that during the period, we carried out by buybacks of ZAR 752 million, which will benefit return on equity and headline earnings per share for the full year. And the dividend declared for the period has been increased by 8.4% to [indiscernible] per share slightly ahead of headline earnings. Retail sales increased 5.4% with same stores growing 3.1%. The warehouse management system implementation at our Western Cape distribution center had a short-term impact of ZAR 175 million on sales. This reduced sales growth by 0.9% in retail. The distribution center is now working optimally and is capable of picking as much as our Centurion distribution center, which is 1.5x its size. The distribution business continued to experience low selling price inflation of 1.5%. Nevertheless, wholesale was up 7% and our preferred bulk distribution business up 31.1% performed strongly. Sales to clicks were up 11.1%, while hospitals were up 2% for the period. [ Bertina ] will elaborate on the detail of each business' performance later in the presentation. This slide reflects the group's total income, which has increased by 6.5% for the period. You can see the total income margin in retail was 70 basis points higher due to the growth in private label volumes. UPD's total income margin was down 50 basis points to 8.9% and which was due to the lower SEP increase, good performance in preferred bulk distribution contracts at a lower margin, partially offset by 2 distribution contracts that were not renewed in the prior year. Overall, the high growth in the distribution business at a lower margin has resulted in the group total income margin being slightly lower by 30 basis points. The cost base in retail increased in the period, partially due to the wage increase of 7%. Higher costs from the WMS implementation to ensure service levels in store were maintained and pharmacy openings. Retail costs grew overall by 6.1%, with new stores contributing 2% to the cost increase with the lower rollout of stores in the first half. Over the last 6 months, we have added 14 Clicks in Unicorn stores and 17 pharmacies to the group. The IFRS 16 interest charge increased as a result of the number of renewals in the period. Comparable retail cost growth overall was well controlled, up 5.4%. In our distribution business, depreciation increased as a result of investments in the warehouse systems. Employment costs were well controlled and the increase reflects a contractors being taken on and moving from other costs. taking other costs and employment costs together, costs increased by 6.8%. Further investments in electric vehicles have been made, and these will be fully rolled out in the second half. Operating costs overall were well controlled. Retail grew trading profit by 11%, with the margin slightly up from last year is the intragroup turnover elimination as a result of the unwinding of the unicorn unrecognized income is taken into account in the prior year. UPD's trading profit increased by 7% and with the trading margin decreasing 10 basis points due to reasons outlined earlier. Overall, the group's trading profit increased by 7.4% to $2.3 billion for the period driven by a good performance in both businesses. Inventory levels for the group were higher by 4 days at 89 days. Retail stock days were 8 days [indiscernible] and increased ahead of underlying sales. Inventory was driven by higher purchases after recovery from the warehouse management systems implementation and investment in new stores and pharmacies. Retail net working capital days increased by 2 days. UPD inventory days at 49 days were 3 days lower than last year and well controlled. Net group working capital decreased by 2 days. This slide shows the movement of cash during the period. As you can see, we started the period with cash of ZAR 3.3 billion reflected in dark blue on the left-hand side. and ended the period with ZAR 1.2 billion on the right-hand side of the slide. The group generated cash of ZAR 3.2 billion highlighted in green before the repayment of lease liabilities amounting to ZAR 456 million, working capital outflows of ZAR 1.4 billion and tax payments of ZAR 651 million. ZAR 311 million was reinvested in capital expenditure across the group. Of this amount, ZAR 186 million was invested in new stores as well as 34 revamps and 15 pharmacy drop-ins and ZAR 125 million was spent on IT and other infrastructure. We returned ZAR 1.5 billion to shareholders during the period through dividends and carried out ZAR 752 million of share buybacks. CapEx of ZAR 1.3 billion is planned for the full year. ZAR 662 million will be invested in our stores and pharmacies. This will include 40 to 50 new Clicks stores and pharmacies and 80 to 90 retail store refurbishments. 54 million will be spent on IT systems and infrastructure. ZAR 88 million of this amount will be invested on UPD IT and warehouse equipment, and we will invest the balance of ZAR 506 million in retail IT systems, including the further rollout of the warehouse management system and online systems. We will continue to grow our retail footprint, grow the number of pharmacies and continue investment in our IT systems. I will now hand over to Bertina.

Thank you, Gordon. I will now take you through our trading performances in greater detail, starting with Click [indiscernible] Turning firstly to the retail performance. This slide reflects the retail sales growth and category contributions. Peaks delivered a muted performance with turnover up 5.4% for the period. This was due to intensified competition, a slow rollout of new pharmacies and the short-term impact of the WMS rollout. Sales turnover in comparable stores was up 3.1%, inflation slowed to 2.3% and volume was up just under 1%. Our 60 stores located in neighboring countries showed pleasing growth of 8.8%. I will now briefly turn to each of the categories on this slide. Our positioning as a trusted health care provider anchors our customer value proposition. Pharmacy remains a key driver of footfall traffic, repeat visits and market share gains. Pharmacy performance has been driven by the growth in chronic scripts and select therapies such as diabetes, which also influenced the margin mix. Improved availability supported the positive performance in Schedules 1 and 2, with skin held up 9%, [indiscernible] held up 13.8% and lifestyle supplements up 18.4%. The strong growth of GLP-1 is continuing with our extensive pharmacy network, providing a clear competitive advantage. Branch of health performance was muted by improved margin. Branded supplements grew by 18% and health foods by 20.1%. Private label ranges such as [indiscernible] and UniHealth, which is our premium supplements range continue to outperform. We launched 17 new optical stock heap limits and are launching further range extensions this month. A sales decline of 1% in baby reflects the impact of low availability and high deflation in diapers and accessories. We actively defended our market share and improved gross margin due to a higher private label contribution of 29% [indiscernible] sales and 56% to the category margin. Although the beauty category remains heavily completed, the latest adverse impact was due to the WMS implementation in the Western Cape, which is our strongest beauty node. We continue collaborating with suppliers to elevate service levels in our beauty [indiscernible] and fragrance [indiscernible] resulting in both stores, delivering results in line with plan. Personal Care delivered a strong performance, up 7.9% despite the substantial impact of lost sales. Our partnerships with key suppliers delivered exceptional outcomes in the hand and body category sales to 12.3%, driven by vasoline, [indiscernible] In the whole freshness category, our exclusive brands grew 26% as we sold 20 million roll-ons, resulting in over 40 million very fresh outfits. Promotional sales up 12.8% was instrumental in the performance of the Personal Care category. Oil performance in general merchandise was up just 2.9%, we achieved category share gains across cotton and small household appliances. This supports differentiation and improves the margin mix. Interestingly, over the 1-week Black Friday promotional period, we sold the equivalent of 6 months' worth of timing here strictness. Turning to market shares. Despite the muted sales performance due to intensified competition, low availability and some supply out of stocks. I am proud that we gained market shares in retail pharmacy, personal care and small household electrical appliances, whilst actively defending our market shares in baby and hair care. The retail pharmacy market share gain share to 24.9% despite the delay in the issue of new pharmacy licenses. We nevertheless opened 7 new pharmacies in half 1 and we have a steady pipeline of licenses. This will enable us to deliver on our targeted number of pharmacies for this year. [indiscernible] declined by 80 basis points due to supply constraints in core lines, sub-manufactured product vehicles and increased competitive pressure. Despite competition, we actively defended our baby market share with standout gains in baby ready-to-drink up 460 basis points and baby wet food, up 140 basis points. We maintained our market share even a decline in baby diapers, which was down 30 basis points. Our market share loss of 100 basis points in skin care is due to the double-digit decline in a major brand in which we have a substantial share that experienced poor availability and a lack of innovation. In response, we have embarked on range and space optimization initiatives and are also reinforcing service levels in our beauty halls and fragrance counters in collaboration with suppliers. We recognize the role that is growing of digital beauty sales and are investing in our e-commerce platform and mobile app to drive personalized customer engagement. We defended our hair care market share, gaining 10 basis points with strong gains in [indiscernible]. [indiscernible] 60 basis points, with strong gains in hand and body up 80 basis points. Oral Health up 60 basis points and body freshness up 70 basis points, a gain in market share of 150 basis points in our legacy category of small household electrical appliances, is accelerating across every subcategory and every measurement period. Standout games were aborted in beverage makers, up 300 basis points food makes up 430 basis points and indoor cookies up 140 basis points. Break value is a key brand pillar has sustained the group during tough economic conditions, such as we are currently facing, our [indiscernible] feel good [indiscernible] and our promotional campaigns to resonate and drive shoppers to our stores and our online platform. Promotional sales were up 8.1% and contributed 47.8% of turnover. Confirmation with the consumer responds to value. In pharmacy, we deliver value with lower cost generic medicines, up 6%, accounting for 58% of sales by value and 72.1% by volume. The weaker value growth of generics is due to the surging demand for GLP-1 products. In the past 6 months, we returned ZAR 527 million in cash back to [ ClubCard ] members to reward them for their loyalty and to ease financial stress. The competitive landscape is evolving due to new entrants and traditional retailers extended -- extending into product categories to capture a greater share of the customer wallet. Competitors are forming novel strategic partnerships to enhance the customer experience. They are also investing in data capabilities to support personalization aimed at shifting customer behavior and to develop targeted loyalty mechanics that enable more precise price investment. We have an African product that states. If the drug be changes, the downs must change. We have recognized the need to adapt to the new competitive reality whilst remaining firmly anchored in affordable, accessible health care, supported by a fit for on-time customer loyalty program and a focused private label and exclusive portfolio. In fact, our private label and exclusive portfolio is a key strategic pillar. It mitigates against the margin impact of increasing our share of pharmacy creates the clear point of differentiation based on consumer trust in the quality of our brands and enables us to maintain our total income margin despite competitive pricing pressures. Over the period, we sold 110 million units of private label and exclusive brands. A fun fact is that we sold enough toilet paper rolls [indiscernible] the earth 100x. The muted performance of private label and exclusives up 4.6% is because 60% of our bath and body sales are accounted for during the peak trading period where we were most impacted by the WMS implementation. We are though reaping the benefits of working with local suppliers to develop ranges in South Africa. This supports the national agenda to drive localization and employment. Our locally produced ranges are continuing to perform exceptionally well, with expert ranges up 35%; Click skin care collections up 11%; and smart by food ranges up 40%. Our rate out ranges grew 75% due to range expansion and improved formulations. We also pursue differentiation through our service offering and in-store elevations. A big focus in this year will be on elevating our means clearly informed by the overwhelming positive sales impact of our pronation campaign and strong growth of our sober main range, up 29%. I am excited at the prospect of our in-store electronic elevation, which is strongly supported by suppliers will achieve in elevating the customer experience whilst also growing both sales and income. Despite its challenges, the Body Shop remains our fourth most profitable exclusive brands. The improved performance of the newly introduced ranges and improved availability is therefore encouraging. The investment in the premium [indiscernible] retail brand continues to add value. with the odd customer spend totaling ZAR 331 million, up 21% over the past 12 months. This is because for every ZAR 1 [indiscernible] cash factor customer earns at Arc, the spend by brand and ZAR 0.72 at a Click store. Our loyalty program is a primary demand driver. It underpins customer affiliation, enabling us to defend and grow market shares. The Kicks ClubCard loyalty program with its strong affinity partners is our most valuable assets with 12.9 million active members, will contributed 83.7% of sales. Over the period, we added a walking 800,000 new active drug card members. [indiscernible] is the most used loyalty program in the mass market and among the youth. The ClubCard program played a significant role in easing financial strain on consumers during tough times, which is the real removed to monthly cash back payments. In the period, our cash back rewards of over ZAR 0.5 billion certainly brought welcome relief to ClubCard customers as to the benefits of our affinity partnership with aging and [indiscernible] to [indiscernible] E-commerce, up 17.9% for the period accelerated strongly in quarter 2, driven by increasing mobile app adoption, personalization enabled by loyalty data and improvements in our performance execution. Our app shoppers contributed 46.5% of online sales with a [indiscernible] option contributing 31% of online sales. We fully implemented LEAP the only modern pharmacy management system in South Africa across all rigs. In response to market environs, we are now marketing with the pharmacy software system to third parties. Over the past 66 months, we have, on average, increased our store count by just over 3 stores per in pursuit of our medium-term expansion target of 1,200 stores. At the half year, we closed on 1,003 Click stores, 795 Clicks pharmacies to UniCare specialized pharmacies and 226 primary care clinics. A week ago, we opened up our 800th pharmacy in [indiscernible], which is rate 5 hours drive outside of Capetown. Our store location strategy, which remains premised on convenience and proximity to customers as key to our consistently broad appeal. Over 53% of sales reside within 5 kilometers of crepes. We increased the number of primary care clinics to 226 and are also extending our virtual doctor network. In UniCare, we are extending space to doctors and partnering with medical funders to provide first-level triage after hours. We are opening another UniCare greenfield site at the end of this month. and completing another UniCare acquisition in May. We remain strongly aligned to the national health care agenda and committed to providing affordable, accessible health to 22 of our convenient format stores are located in [indiscernible] areas, accounted and accounting for 23.4% of turnover. That completes the review of the retail business. I will now provide an overview of our distribution trading performance. Wholesale turnover was up 7%, boosted by the improved purchasing compliance from its core wholesale customers. Clicks accounted for 16.5% of UPD's fine wholesale turnover, up 11.1%. Click has improved purchasing compliance of 98% is in line with our internal targets. This is positive for [indiscernible], but less so for competitors will benefit from expires in prior periods. [indiscernible] will continue to benefit from the growth in clicks as it increases its pharmacy counts in H2. The hospital channel remains constrained by controlled supply rather than demand as they manage their ethical generic mix and inventory levels. Purchasing compliance that we have stabilized due to improved service levels. Over the period, UPD's market share of the independent app private hospital channel improved from 30% to 33%. The dedicated hospital key account management structure which we introduced over a year ago, is yielding positive results. The stabilization of LEAP pharmacies is due to a relaunch link offer and dedicated resourcing. The revised frontal offer to independent pharmacies is beginning to stimulate sales in that channel. Whilst we are pleased with the improved trading performance, expense management efficiency extraction and other income gains, there remains room for improvement. The delivery of the strategic initiatives outlined next together with superior service to all [indiscernible] customers will deliver the recovery of UPD's wholesale market share. Quality regulatory compliance and service excellence underpins UPD's performance. Operational stability with the on-time and in-full metric at 96.4% and customer info rate at 99.3% resulted in improved urgency compliance or 5 wholesale customers, whilst preferred bulk contracts delivered a truly stellar performance However, the loss of the 2 bulk contracts adversely impacted total [indiscernible] turnover. Value growth continues to be impacted by the higher volume growth of generics, which contributed 76.9% to [indiscernible] fine wholesale sales. Our strategic initiatives are progressing broadly in line with plan. I will highlight a few things. Medical consumables remain a strategic growth opportunity. The acquisition of a medical consumables business to fuel this opportunity has been finalized. We have completed the integration process. The sales targets are being pursued in a disciplined manner, and we have extended our inventory pipeline to ensure that we have the requisite stock mix for scaling this in our core hospital channel as well as the private sector in Southern Africa. In December, a cross-stop facility located at the retail DC became fully operational with the early benefits already evident. [indiscernible] facility enables us to service our core wholesale customers in the [indiscernible] note much more effectively, which will also reduce byways to competitors. In low margin business such as UPD, a relentless focus on efficiencies and experience mentioned is critical. Over the past few years, we have worked on route optimization and on reducing our fuel costs through our electric vehicle conversion program. By the end of this month, a 6% of our wholesale fleet will comprise of EVs going 714 of total kilometers cuts. Over the past 12 months, fuel as a percentage of transport costs have already reduced from 40% to 35%. UPD's strong top line momentum accelerated in quarter 2, driven primarily by preferred bulk sales. The business will benefit from a stronger Clicks pharmacy opening program in half 2. improving link purchasing appliance and the ramp-up of medical consumables. Profitability will remain under pressure, gets the UPD team are focusing on maintaining service excellence working capital improvement and disciplined cost mentioned. This completes the review of our trading performance for the period. As always, I am inspired by the proud brand ambassadors in our company. The [indiscernible] impact tested our resilience but our people in our stores, seats, I regional offices and [indiscernible], who are unwavering in their commitment to getting us through that period. On behalf of our Board and the executive teams, I would like to thank each employee, team and their families for their individual and collective contribution to our results. I will now conclude the presentation with the outlook. It will appear that the only constant is change. In early January, most economists were cautiously optimistic about the economic outlook for South Africa. Because South Africa imports most of its crude and refined oil products, any increases in fuel prices will have an age effect on the costs of transport and food. In turn, this will adversely impact inflation and interest rates leading to depressed consumer spending. We too will be affected by fuel price increases. The investment to convert more than 80% of the UPD wholesale fleet [indiscernible] is already delivering fuel cost savings. This will enable us to mitigate against a fuel surcharge for our customers whilst also supporting our sustainability agenda. In half 2, we will also be absorbing the impact of the very low SEP increase primarily in UPD but also [indiscernible] a proven capability to trade positively through constrained trading conditions. This is because of fiercely loyal truck card customers, extensive private label and exclusives portfolio and our strong market share in the [indiscernible] of retail categories. The investments made in [indiscernible] are attracting new customers to Clicks. UniCare is extending its service offering by creating space in [indiscernible] stores for doctors. The cold and flu season lies ahead in May, we will trial our on-demand over-the-counter medicine delivery service, which will be fully pharma compliant. We will achieve our target of opening 40 to 50 new stores and 40 to 50 pharmacies this year based on data-driven insights. Despite some delays, we will open 2 additional UniCare format pharmacies by the end of May and one more by the end of this year, taking our total unit count to 5 by the end of this financial year. We are on track to pilot team clearly differentiated concept stores in this year. UPD has a clear targeted plan to grow sales of its higher-margin medical consumables business in its core [indiscernible] and in the Southern African private sector. Scale is important because it provides the opportunity to pursue efficiency gains. Earlier, I showed some of UPD's strategic initiatives. All our retail businesses and shared services teams are executing plans aimed at stimulating cells and margin improvements as well as the sustainable cost management initiatives to create the necessary leverage to enhance profits. We wrestled with the earnings guidance because of the high levels of uncertainty and volatility as a result of geopolitical events, which will impact on inflation, interest rates, consumer spend, supply chains, product margins, our costs in the months ahead. These are the factors that weigh on us in [indiscernible] guiding for an increase in diluted headline earnings per share for this financial year of between 4% and 9%. That concludes the presentation. Thank you so much for taking your time to listen to us. We are available to take your questions or your comments. So I'm now handing over to [indiscernible] will facilitate the Q&A.

Firstly, competition in the drug retail space appears to be intensifying, particularly around loyalty programs. how is the group thinking about maintaining its competitive position? And could this lead to any evolution of the Clicks [indiscernible] offering over time.

I'll take that question. Michael, thank you very much. That's an excellent question. First, I guess I'm buoyed by the increase in our pharmacy market share. That's probably the clearest indication of where not we are winning against the decoration. But what will be in edition to that? The first is we are excited at the prospect of driving our over-the-counter on-demand medicine delivery service as we've said in [indiscernible] Secondly, we are going to be hitting our target of up to 60 pharmacies in this financial year. Very well on track of this with this, and you already have a fair number of those licenses already in hand. Thirdly, we continue to see the exceptional loyalty of [indiscernible] pharmacy. When we talk about [indiscernible] 83.7% of total sales in pharmacy, they're in over 87%. And then fourthly, we are extending UniCare, which is really a specialized pharmacy format, and we are hopeful that by the end of this year, we will get to 5%. Definitely, we know that by maybe will get to 4.

Second question. As the WMS will be rolled out to the Durban DC Next, what key lessons have you taken from the pectin implementation? Should we expect any further disruption during the rollout?

I can take that. And in terms of the rollout to the Cape Town, it's not a start-up from 0 again. So any bugs are operational issues, but are being earned out. I think the second thing to bear in mind is that Cape Town is in terms of complexity, our most complex distribution center, and we've tested every aspect of the warehouse management system over the last few months. And with put in moved people from Cape Town to take the Durbin staff through how to work with flat with the new system. So there's very good change management. So in short, we are not expecting to experience the same level of issues that we had with [indiscernible] it's at a quieter part of the year. I think the last aspect to just bear in mind is the relative size of the DC. So Durbin is about 1/3 of the size in terms of Cape Town in volume. So there's a very good plan to mitigate or alleviate some pressure when we go live on the stores that Durbin serves. So we expect that Durbin the next DC will be successful.

So if I may, maybe just add to some of that because I think [indiscernible] you're asking is that we learned. The first, I think that we have learned is take a bit more time to reconsider if you've handed where do you go? So complexity of the distribution center, I think, will be 1 of the key factors that we take into account. And as Gordon said, Durbin is the least complex of all of the retail DCs. The second one is have a plan B, but also GMC. The third one, I think, is that we've already put in place work towards our micro performance centers. which will alleviate the pressure on the Durbin DC when we go live. And then fourthly, part of our plan is that if anything were wrong, which we do not anticipate at all because we've been stable now for 2 months flat is that we are able to serve August our Durbin customers sorry, from both legally and then also buy Capetown the Eastern [indiscernible] which is really serviced out of the urban DC at the moment.

His Third question Thank you for the full year guidance. Could you maybe give us a bit of color on the key assumptions, particularly around diesel prices and inflation.

Well, we did outline the impact of what the diesel plus increase is going to be on our bottom line. But I don't think that is the -- that is an impact, but it's not the major impact. It's also what price increases that suppliers are going to be looking to pass through to ourselves. -- and the impact on the wider economy because it's the consumer has less money in the pocket. It's how much are they going to pull back on spend. So just now inflation remains fairly muted. We expect it to go up in terms of the cost price inflations that were passed through or that suppliers want to pass through, we'll always negotiate for a period of time, but it is going to have some I think the more worrying impact is the general impact on the consumer going forward.

His fourth question to mentioned the rollout of on-demand OTC net some delivery from May. Could you provide more detail on the scope initial regions? And how do you see this scaling over time?

So I mean, we're going to do the rollout trial from May, well on track on that. Much of the work Michael has been around really understanding the -- how we ensure that we are compliant from the very beginning. We will be first to market with us. And so I think it's important that we do that. In terms of the mechanics of all of that. I mean that's what the team are currently firming up on when we've got a bit more detail on that, we will let you guys all know about their [indiscernible].

Then his fifth question and the last question of this session. Could you elaborate on the [indiscernible] pharmacy licenses and how you expect accrual time lines to [indiscernible] going forward?

How long is a piece of [indiscernible] there were 2 things really. I mean there are resource constraints within [indiscernible] and the Department of Health. Just in terms of the inspectors, you need a physical inspection of the site. The second one really is that there was a bit of an irregular meeting schedule for some reasons that were completely understandable, such as, for example, tragedies in some of the family members that sit on that licensing committee. But we are really hoping that the meeting schedule will be more regular going forward. The important I think at this stage is to note that we have a fair number of the licenses to support our rollout program of pharmacies for the remainder of this year.

And we have 2 questions on the same topic from [indiscernible], both asking for some insight on the retailers period trading. Has it improved from a circa 3% print from the last 6 weeks of the first half.

Bottom line is, yes, it has improved from the 3% print. It's still not where we -- we always want it higher. But it's still fairly early since we've introduced the additional club card rewards at the end of February. So on the deep cut deals, which has been performing particularly well for the products that we put on promotion there, and we're seeing that our suppliers are quite excited about that. and wanting to speak to us more about support around those sorts of deals. That's definitely ahead of the 3% that we saw in the last 6 weeks.

And [indiscernible] just to add to that. I mean we haven't really had a high level of new store openings since the first half. But today, for example, we're going -- we're opening our doors today. I think between -- I think 5 or so today. [indiscernible] actually goes next week with 28, our second -- our third UniCare store opens next week.

So you partially answered the first part of Michael Jackson Bank of America's question, which is how is your rewards program performing since implementing changes in Q1 and should we expect an increase in promotional cadence for H2. But he also asked, will this impact gross margin negatively in H2? Or can you offset this by growing private label further?

Partially, the offset will always be an ongoing private label further, but it's also going to be about how you use the revised card offer in a much more selective way, as opposed to broadly. So that's some of the work that the team is looking at the moment.

Yes, tell from SCG asks another question. Retail wage increases seem quite high in the context from moderate CPI for now, what led to such a high negotiated increase. It's something that happened more than 2 years ago. So it was a multiyear deal. And most certainly, what we have done is that we have had discussions with the negotiation team. they commence the negotiation with the new deal, which will be implemented in July month. So the process has kicked off. [indiscernible] from Integral Asset Management is congrats on continued store growth and good results and a very difficult trading environment and deciding on the split between dividends and a share buyback or value to [indiscernible] share.

We never disclosed what that value is. We do have a model, and we base it on we are expected -- our forecast results. And that's that's put to the Board by management and approved by the Board. But that's not [indiscernible] a number that we disclose.

[indiscernible] Investec. We've answered a couple of these questions, but he says thanks for the opportunity to ask him. [indiscernible] has lagged pharmacy. Could you provide some color on the competitive pressures faced currently, which categories and entities do these procure stem from? Does this mean sustain promotional activity going forward?

I don't think sustained promotional activities require it. It essentially has been in the more premium business and supplements range. And that's the reason we're accelerating our range extensions with the [indiscernible], which is really performing exceptionally well. I may also say, I mean, we've seen a fantastic performance out of GMC over the last couple of months. I spoke to our Head of Healthcare last night, and he had just come back from even he came to [indiscernible] the should and [indiscernible] the team are working really, really very hard on this. [indiscernible] and supplements, I think we're quite clear in terms of what the areas, but there were -- we had some core lines that were out of stock. And those are some of the areas that we are retaining to at the moment. Sorry, we're getting multiple questions on the [indiscernible] I hope we've answered people's questions. [indiscernible] Citi has [indiscernible] if we can give an inflation outlook for half 2 and for FY 2027, the mirror that I'm looking at is super opaque on that one. I mean, kind of just say, I mean the reserve bank kind of signaled that you may be looking at inflation in closer to 4% to 4.5% by -- probably by around by the end of May. It's unclear to us at this stage as to what that would mean. I mean, clearly, I think suppliers are already knocking on the doors, talking about price increases, all of us in our personal capacities, we have already had some of our domestic service providers talk to us about fuel surcharges. So I think inflation is seeing up, but it really is all going to depend on what happens to not be selling the contract what happens in the Middle East.

[indiscernible] asks that we're able to share sales and profit of the medical consumables business.

There is a plan. The reason we are not talking about any shifting the guidance as far as GPD is concerned is because those plans must not be realized. And so I think it's early days, the team. I must say we put together a really impressive plan. They've already started engagements with hospitals, both in the kit as well as within these hospital space. Let's just say the margin is significantly and substantially higher than what the margin would be within [indiscernible]

[indiscernible] from [indiscernible] Private Wealth asks private label growth was only 4.6% despite its margin benefit. What held back the growth in pharmacy private label is still relatively low versus generic volume. One of the main barriers to scaling private label opportunity there. The biggest impact on private label growth over the period was because 60% of our bath body, which is a massive category for us. those cells really happen within over the peak trading period. And so that was a major impact. What would we be doing?

I mean the constraint in pharmacy would be there's a regulatory process that you have to go through. You will know that we disinvested of unicorn and we no longer action on any of those products. And so it's the work [indiscernible] we do with the Unipharma team. in terms of making a broader range available. And now there is specific categories such as metal health, which are much more challenging to shift the patient that is on an originated product. There's probably some of the feedback that I give on that. Sorry, the final thing that I was just going to say is, of course, as well as the surging growth of the GLP-1s, which are originated, but at this stage.

[indiscernible] Asset Management. The [indiscernible] to [indiscernible] at [indiscernible] as a move to integrate electric trucks into their logistics fleet.

Maybe meaning the retail business as well into the retail business swap. I think orders help you currently.

Sorry. The trucks that used in UPD are much smaller. We are trialing EVs in the retail fleet, but just now the economics of the larger trucks versus the traditional ICE vehicles aren't quite there just yet. But it is something that we are looking at very closely because the economics in the larger trucks are changing very, very quickly. So a few years ago, the small electric vehicles probably wouldn't have been feasible for UPD, and that's just changed in the last couple of years. That makes it very attractive. And fortuitous, just now given the recent events. But it is something that we are looking at, but we're not quite there yet.

[indiscernible] Management says the 1,200 stores, medium-term target. How should we think about the longer-term target or runway?

Look, I mean, we're going to get to around about at least 1,040 Click stores probably by the end of this financial year. So the target achieving the 1,002 target is in sight. And we've said once there's close proximity to that target, we will be providing an updated target. So differently, there's a clear understanding in our business that, that is not the final target. We will be providing that target upwards closer to reaching the target itself.

I have a few questions [indiscernible]. Has the move to a [indiscernible] changed how you think about promotions and margin management also from a customer perspective, what has been the impact on customer frequency and basket science.

The cash bank monthly payment cycle was really. We did a lot of research and benchmarked ourselves. And it became clear especially in a constrained economic environment. Customers didn't have enough time to wait for 2 months off before the [indiscernible]. And so that's important, I think, to assist the customer. Actually, when we look at it, ClubCard customer contribution to sales is up. In fact, even as I speak, I was just looking at last year. It's beyond the contribution that I outlined as of the half year period. So definitely, that change in shift in the [indiscernible] program does seem to their fruits.

The WMS impacted the DC MPS to have increased their inventory levels with double digits ahead of top line. Can you give some color on clearing inventory out and any potential impact on margins?

So the inventory that was brought in was really as a result of not being able to get the stock in during the implementation. So we made a decision to push stock into the DC once things have settled down into January. So it's not a impact that we -- the inventory levels that we have shouldn't give rights to a significant need for any sort of markdown or clearance, et cetera. So it's not something that we're particularly worried about at this point.

Actually, [indiscernible], I may make the point to say that come the price increase to be particularly I think would be continuous that we have the stock.

Yes. But I think we didn't plan on that for the opportunity but [indiscernible]

Can you give a bit more detail on the 10 differentiated concept stores you plan to [indiscernible]

Well, I mean, first of all, why would we even look at this as opposed to saying, do you just change a clicks and make it smaller. It's because we really want to be true to what the Kicks brand is all about and the on integrated front up and health care offering. The second bit that Clicks really needs -- I mean, I don't think we've got some smaller source, but I mean how you will Clicks really has a store size, probably a minimum of 500 square meters. We can do [indiscernible], but I think it's in very specific lifestyle things. That immediately constrains where you will be able to put this up. So we [indiscernible] look at some of the most highly most densely populated areas in South Africa, where you have massive transport hubs those are the areas that we're looking at. And then, of course, we saw in some of the rural areas where the competitors are not.

And a final question on [indiscernible]. But can you get some color on CEO succession planning, particularly in the context of the group's executive retirement policy of age 63?

I think I can say I was actually checking the IR, and you didn't mention it, but the Board has asked and I agreed that I would stay on as CEO until the end of August 2028. And we have started the process of both identifying and preparing succession candidates within the group, which obviously is much of the board Importantly, I think to say is that we've reinstated the nomination committee. We had the first nominations come here about a week ago, and that is a primary focus of the Chairman and of the Nominations Committee.

[indiscernible] has another question. In 2023, you acquired a software company called 180 degrees. Does this company have anything to do with the WMS?

No, we did not. It had a lot to do with a very successful project called LEAP, which is the only modern pharmacy management system in South Africa. It's really the implementation went extremely smoothly. And of course, now we've got overwhelming demand from the private sector, and we are starting to process to markets and roll that out within the private sector.

[indiscernible] With regards to UPD. You mentioned subdued performance in the hospital and independent segments. Could you please touch on the strategy to raise the subdued performance.

Both in the hospitals really it's about the difference between value and volume because hospitals are definitely managing their ethical generics mix as well as the inventory levels across their network. So that's the one part. What are we doing to try and increase our size of basket within hospitals? That's really all about the medical consumables. So the engagements have begun in terms of extending that into the hospitals. And we'll -- we are hopeful [indiscernible] that we are making and we'll be able to make in growth in the independent space. The team have just started about 4 weeks ago in the revised [indiscernible] offer and the way which has been communicated, and I must say the early uptake is really, really encouraging. So that's good to see that we are able to now look at arresting not only [indiscernible] but I think improving the performance in the independent pharmacy space.

A technical question for Gordon from a [indiscernible] how should we think about the growth in the finance cost line post double-digit growth over in the first half?

That's really all about the early share buybacks that we did this year compared to the prior year. So the IFRS 16 cost [indiscernible] been coming down some better resource set by the early buybacks we did in the first quarter.

We're. Running out of time. So I'm going to just ask one final question from [indiscernible]. What do you think would need to go right for Clicks [indiscernible] to again grow around 13% to 14% going forward in the medium term? And what is your medium-term target for [indiscernible]?

Well, I think what needs to go right -- what needs to right, probably is that we get the pharmacies as expected. That's critically important because it's the anchor and the [indiscernible] driver. Secondly, I would probably say it would be difficult to think that something that operationally we need to do differently, to be honest with you, because I look, for example, just a shrink, it's half of what it was a year ago. I mean, a year ago, we were already best-in-class globally. So I would have said the biggest for me would be to actually get the pharmacy licenses. The final one would be, I think we're going to have to be pretty tough with suppliers. We've chosen where they invest disproportionately. And I don't think it's only our company. I think it's all of the other retailers that are knocking on those doors and saying, that was most unfortunate, but you long to have to give us the same. Let's see what they do. Now it would seem to me that we could go on for 2 more days with you guys. Thank you so much for the quality of your questions. We have responded to those that we have. Sue will get back to you if we haven't responded. So can I just say thank you once again for your time and all the best.